首页> 美国卫生研究院文献>PLoS Clinical Trials >CACNA1C Risk Variant and Amygdala Activity in Bipolar Disorder, Schizophrenia and Healthy Controls
【2h】

CACNA1C Risk Variant and Amygdala Activity in Bipolar Disorder, Schizophrenia and Healthy Controls

机译:双相情感障碍,精神分裂症和健康对照者的CACNA1C风险变异和杏仁核活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectivesSeveral genetic studies have implicated the CACNA1C SNP rs1006737 in bipolar disorder (BD) and schizophrenia (SZ) pathology. This polymorphism was recently found associated with increased amygdala activity in healthy controls and patients with BD. We performed a functional Magnetic Resonance Imaging (fMRI) study in a sample of BD and SZ cases and healthy controls to test for altered amygdala activity in carriers of the rs1006737 risk allele (AA/AG), and to investigate if there were differences across the diagnostic groups.
机译:目的多项遗传学研究提示CACNA1C SNP rs1006737与双相情感障碍(BD)和精神分裂症(SZ)病理有关。最近发现这种多态性与健康对照和BD患者的杏仁核活性增加有关。我们对BD和SZ病例样本以及健康对照者进行了功能性磁共振成像(fMRI)研究,以测试rs1006737风险等位基因(AA / AG)携带者的杏仁核活性是否发生改变,并调查是否存在差异诊断组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号